ECONOMIC-ANALYSIS OF ALTERNATIVE TREATMENTS FOR PERSISTENT GASTROESOPHAGEAL REFLUX DISEASE

被引:28
作者
HILLMAN, AL
机构
[1] Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA
关键词
COST-EFFECTIVENESS; GASTROESOPHAGEAL REFLUX DISEASE; OMEPRAZOLE; RANITIDINE;
D O I
10.3109/00365529409105374
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The economic evaluation of new medicines is increasingly important for pricing, registration and selection for use. A decision-analytic strategy was performed to assess the economic impact of antacids alone (phase I therapy), and in combination with either omeprazole, 20 mg once daily, or ranitidine, 150 mg twice daily, for patients with persistent, symptomatic gastro-oesophageal reflux disease of grade II or more (Savary-Miller classification). Data were obtained from published literature, an expert panel of gastroenterologists and actual payments by a private insurer in the USA. Over the 7-month period of the analysis, omeprazole reduced both symptoms and overall costs when compared with ranitidine or antacids. Consequently, the cost per symptom-free month was 43% lower with omeprazole than with ranitidine. Thus, omeprazole should be considered as the initial therapeutic approach for patients in whom phase I therapy fails.
引用
收藏
页码:98 / 102
页数:5
相关论文
共 13 条
  • [1] BLUM AL, 1986, NEW ENGL J MED, V314, P716
  • [2] THE EFFECT OF PRESCRIBED DAILY DOSE FREQUENCY ON PATIENT MEDICATION COMPLIANCE
    EISEN, SA
    MILLER, DK
    WOODWARD, RS
    SPITZNAGEL, E
    PRZYBECK, TR
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (09) : 1881 - 1884
  • [3] HEADING RC, 1989, SCAND J GASTROENTERO, V24, P33
  • [4] HEALING AND RELAPSE OF SEVERE PEPTIC ESOPHAGITIS AFTER TREATMENT WITH OMEPRAZOLE
    HETZEL, DJ
    DENT, J
    REED, WD
    NARIELVALA, FM
    MACKINNON, M
    MCCARTHY, JH
    MITCHELL, B
    BEVERIDGE, BR
    LAURENCE, BH
    GIBSON, GG
    GRANT, AK
    SHEARMAN, DJC
    WHITEHEAD, R
    BUCKLE, PJ
    [J]. GASTROENTEROLOGY, 1988, 95 (04) : 903 - 912
  • [5] AVOIDING BIAS IN THE CONDUCT AND REPORTING OF COST-EFFECTIVENESS RESEARCH SPONSORED BY PHARMACEUTICAL COMPANIES
    HILLMAN, AL
    EISENBERG, JM
    PAULY, MV
    BLOOM, BS
    GLICK, H
    KINOSIAN, B
    SCHWARTZ, JS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (19) : 1362 - 1365
  • [6] HILLMAN AL, 1992, ARCH INTERN MED, V152, P1467
  • [7] KLINKENBERGKNOL EC, 1987, LANCET, V1, P349
  • [8] GASTRO-ESOPHAGEAL REFLUX - PATHOGENESIS, DIAGNOSIS, AND THERAPY
    RICHTER, JE
    CASTELL, DO
    [J]. ANNALS OF INTERNAL MEDICINE, 1982, 97 (01) : 93 - 103
  • [9] OMEPRAZOLE OR RANITIDINE IN THE TREATMENT OF REFLUX ESOPHAGITIS - RESULTS OF A DOUBLE-BLIND, RANDOMIZED, SCANDINAVIAN MULTICENTER STUDY
    SANDMARK, S
    CARLSSON, R
    FAUSA, O
    LUNDELL, L
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1988, 23 (05) : 625 - 632
  • [10] 2 DOSES OF OMEPRAZOLE VERSUS PLACEBO IN SYMPTOMATIC EROSIVE ESOPHAGITIS - THE UNITED-STATES MULTICENTER STUDY
    SONTAG, SJ
    HIRSCHOWITZ, BI
    HOLT, S
    ROBINSON, MG
    BEHAR, J
    BERENSON, MM
    MCCULLOUGH, A
    IPPOLITI, AF
    RICHTER, JE
    AHTARIDIS, G
    MCCALLUM, RW
    PAMBIANCO, DJ
    VLAHCEVIC, RZ
    JOHNSON, DA
    COLLEN, MJ
    LYON, DT
    HUMPHRIES, TJ
    CAGLIOLA, A
    BERMAN, RS
    [J]. GASTROENTEROLOGY, 1992, 102 (01) : 109 - 118